Dementias Platform UK

As the complexity of data-based #dementia #research increases, get the hands on experience you need to take your data analytic skills to a new level. Advanced Health Data Academy 4-8th Nov. Apply: https://zurl.co/eMVU Learn more about our training: https://zurl.co/5wCM

As the complexity of data-based #dementia #research increases, get the hands on experience you need to take your data analytic skills to a new level. Join our online Advanced Health Data Academy from 4th-8th November 2024! Apply now: https://zurl.co/eMVU Learn more about DPUK training opportunities: https://zurl.co/5wCM #data

Enabling more researchers to access and analyse valuable study data is key to making breakthroughs in dementia research. DPUK supports researchers with affordable online courses focused on working with longitudinal large scale data sets. Our next 5-day online virtual academy will run between 4th and 8th November 2024 and is suitable for more experienced data analysts. Applications to participate now open: https://zurl.co/d2UM Learn more about DPUK's Advanced academy: https://zurl.co/Fscm

Commenting on the UK's decision to license #Lecanemab but not use it in the NHS, DPUK's Professor Vanessa Raymont said: "This is the first drug that is approved in the UK that has the potential to change the course of the disease and have real impact on the progression of any memory impairment. However, it is clear the NHS still isn’t ready to roll out treatments like this. More ground-breaking treatments are coming and this is a great opportunity for us to offer improved care for all patients with Alzheimer's disease. “New treatments bring hope but they will mean nothing if we don’t urgently fix dementia diagnosis, which is why research projects like the Blood Biomarker Challenge and our READOUT programme – which aims to bring a blood test for dementia to the NHS within 5 years – are so important. A dementia diagnosis is important because it unlocks access to personalised care and support, allowing people and their families to plan for the future.”#dementia #drug #UK #NHS Read more: https://lnkd.in/d6RzpbnQ

"Whatever your view of the decision taken by the UK MHRA and NICE on dementia drug Lecanemab, the key take-away is that Lecanemab has been licensed." "This is encouraging for the development of next-generation therapies that will provide greater benefit at less risk. There are grounds for optimism that these next-generation drugs will become available on the NHS." "It is crucial that the UK remains laser-focused on developing these treatments.” - Prof John Gallacher, Director, Dementias Platform UK. https://zurl.co/rpdk

Data analyst training opportunity alert! DPUK runs two academies a year to provide training at beginner and advanced levels. We have trained more than 250 researchers on our programmes to date. Our academies offer participants affordable online training and experience of working with cohort data. Join us online between 4th and 8th November 2024 and hone your data analytical skills. Aimed at more experienced data analysts, our Advanced Data Analyst Academy features presentations, lectures and guided tutorials, group working and hands-on big data exercises aimed at helping researchers enhance their data science skillsets. Find our more about DPUK's Advanced academy: https://zurl.co/Fscm Apply now: https://zurl.co/d2UM #dementia #research #data

Prof Sarah Bauermeister PhD CPsychol is in Singapore this week meeting @GlobalGenMed (Int. Health Cohorts Consortium). Working to create a global platform for #translationalresearch. Members have 100,000+ cohort groups. There's strength in numbers for #research. #dementia #health #data #CohortsToClinics

Really excited to be attending the PRECISE-IHCC conference next week in Singapore on behalf of Dementias Platform UK and International Health Cohorts Consortium (IHCC) presenting news of our DPUK-IHCC Remote Mentoring Programme for ECRs. Also meeting new collaborators for our NIH-funded Covid Global Mental Health Consortium (CGMHC).

We are building a brand new team to deliver the £4.5 million READ-OUT programme. Come and join us and be a part of a revolution which will establish the real-world use of blood biomarkers of dementia. If you have a research background in dementia, neurodegeneration, or neuroscience these roles could be for you (Final few days to apply for research roles): Postdoctoral Research Assistant: REAL world Dementia OUTcomes (READ-OUT) (x 2 posts) APPLY HERE BY MIDDAY 19TH AUGUST 2024: https://zurl.co/CPJB Research Assistant: REAL world Dementia OUTcomes (READ-OUT) APPLY HERE BY MIDDAY 19TH AUGUST 2024: https://zurl.co/A9NL We are also looking for an outstanding project manager with experience in managing clinical trials or complex multi-site research projects to lead the planning and implementation of the programme. Project Manager: REAL world Dementia OUTcomes (READ-OUT) APPLY HERE BY MIDDAY 2ND SEPTEMBER 2024: https://zurl.co/ceDK All READ-OUT roles will be based at Department of Psychiatry, Oxford, OX3 7JX. Learn more about the READ-OUT project: https://zurl.co/gs6t

The Lancet's latest report on #dementia has two new factors in developing dementia: hearing loss & air pollution. Read More: https://zurl.co/vBsQ. Both risks featured in recent DPUK #GreatMindsLive events for research volunteers helping with research. #hearingloss #pollution